Table 4.
Event Rates of Incident Clinical HF, CVD Events and CVD Death, and All‐Cause Deaths Across Visit 3 HF Stages (N=1782) Compared With Stage A as the Sole Reference Group
| HF Stage | 0 | A | B | C/D | Pooled |
|---|---|---|---|---|---|
| Clinical HF | |||||
| Cases/no. at risk | 3/71 | 48/386 | 231/1164 | NA | 282/11621 |
| Total‐person‐y | 1276 | 6480 | 17 913 | NA | 28 793 |
| Event rates* | 2.4 (0.8–7.3) | 7.4 (5.6–9.8) | 12.9 (11.3–14.7) | NA | 9.8 (8.7–11.0) |
| Hazard ratio † | Referent | 1.75 (1.28–2.39) | NA | … | |
| CVD ‡ | |||||
| Cases/no. at risk | 1/71 | 61/379 | 257/1127 | 42/132 | 361/1709 |
| Total‐person‐y | 1294 | 6297 | 17 384 | 1724 | 26 698 |
| Event rates* | 0.8 (0.1–5.5) | 9.7 (7.5–12.5) | 14.8 (13.1–16.7) | 24.4 (18.0–33.0) | 13.8 (12.2–15.0) |
| Hazard ratio † | Referent | 1.48 (1.12–1.95) | 2.66 (1.79–3.96) | … | |
| CVD death | |||||
| Cases/no. at risk | 2/71 | 19/386 | 115/1164 | 44/161 | 180/1782 |
| Total‐person‐y | 1307 | 6805 | 19 469 | 2239 | 29 820 |
| Event rates* | 1.5 (0.4–6.1) | 2.8 (1.8–4.4) | 5.9 (4.9–7.1) | 19.6 (14.6–26.4) | 6.0 (5.2–7.0) |
| Hazard ratio † | Referent | 2.06 (1.27–3.35) | 7.41 (4.30–12.75) | … | |
| All‐cause mortality | |||||
| Cases/no. at risk | 10/71 | 92/386 | 402/1164 | 94/161 | 598/1782 |
| Total‐person‐y | 1307 | 6805 | 19 469 | 2239 | 29 821 |
| Event rates* | 7.6 (4.1–14.2) | 13.5 (11.0–16.6) | 20.6 (18.7–22.8) | 42.0 (34.3–51.4) | 20.1 (18.5–21.7) |
| Hazard ratio † | Referent | 1.49 (1.19–1.87) | 3.24 (2.43–4.34) | … | |
Heart Failure stage A was the referent group because of too few events in the Stage 0 group. We excluded prevalent MI from stage B (N=89) for these analyses. Individuals with prevalent CVD in each stage were excluded for analyses of CVD incidence. CVD indicates cardiovascular disease; HF, heart failure; and MI, myocardial infarction.
*
Per 1000 person‐y (95% CI).
†
Age‐ and sex‐adjusted hazard ratios (95% CI) for baseline HF stages.
‡
Excluding HF.